Evidence map›Paper›PMID 25255221›Full record

ArticlePloS one2014

External validation of the Garvan nomograms for predicting absolute fracture risk: the Tromsø study.

Luai A Ahmed, Nguyen D Nguyen, Åshild Bjørnerem, Ragnar M Joakimsen, Lone Jørgensen, Jan Størmer, Dana Bliuc, Jacqueline R Center, John A Eisman, Tuan V Nguyen and 1 more

Open access · goldAbstract readValidation Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Pooled it
  2. Article
  3. Approach to the Patient With Bone Fracture: Making the First Fracture the Last.The Journal of clinical endocrinology and metabolism · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Predictive performance of the Garvan Fracture Risk Calculator: a registry-based cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
  8. A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Article
  9. Observational
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Prevention and treatment of bone fragility in cancer patient.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
    Review
  16. Overview of Fracture Prediction Tools.Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Luai A AhmedDepartment of Health and Care Sciences, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
Nguyen D NguyenOsteoporosis & Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia.
Åshild BjørneremDepartment of Health and Care Sciences, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
Ragnar M JoakimsenDepartment of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway; Medical Clinic, University Hospital of Northern Norway, Tromsø, Norway.
Lone JørgensenDepartment of Health and Care Sciences, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
Jan StørmerDepartment of Radiology, University Hospital of Northern Norway, Tromsø, Norway.
Dana BliucOsteoporosis & Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia.
Jacqueline R CenterOsteoporosis & Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia; Department of Endocrinology, St Vincent's Hospital, Sydney, Australia; St. Vincent's Clinical School, UNSW Australia, Sydney, Australia.
John A EismanOsteoporosis & Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia; Department of Endocrinology, St Vincent's Hospital, Sydney, Australia; School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia; St. Vincent's Clinical School, UNSW Australia, Sydney, Australia.
Tuan V NguyenOsteoporosis & Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia; St. Vincent's Clinical School, UNSW Australia, Sydney, Australia; School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia; Centre for Health Technologies, University of Technology, Sydney, Australia.
Nina EmausDepartment of Health and Care Sciences, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
Garvan Institute of Medical Research · AUUiT The Arctic University of Norway · NOUniversity Hospital of North Norway · NOThe University of Sydney · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbsolute risk estimation is a preferred approach for assessing fracture risk and treatment decision making. This study aimed to evaluate and validate the predictive performance of the Garvan Fracture Risk Calculator in a Norwegian cohort.

methodsThe analysis included 1637 women and 1355 aged 60+ years from the Tromsø study. All incident fragility fractures between 2001 and 2009 were registered. The predicted probabilities of non-vertebral osteoporotic and hip fractures were determined using models with and without BMD. The discrimination and calibration of the models were assessed. Reclassification analysis was used to compare the models performance.

resultsThe incidence of osteoporotic and hip fracture was 31.5 and 8.6 per 1000 population in women, respectively; in men the corresponding incidence was 12.2 and 5.1. The predicted 5-year and 10-year probability of fractures was consistently higher in the fracture group than the non-fracture group for all models. The 10-year predicted probabilities of hip fracture in those with fracture was 2.8 (women) to 3.1 times (men) higher than those without fracture. There was a close agreement between predicted and observed risk in both sexes and up to the fifth quintile. Among those in the highest quintile of risk, the models over-estimated the risk of fracture. Models with BMD performed better than models with body weight in correct classification of risk in individuals with and without fracture. The overall net decrease in reclassification of the model with weight compared to the model with BMD was 10.6% (p = 0.008) in women and 17.2% (p = 0.001) in men for osteoporotic fractures, and 13.3% (p = 0.07) in women and 17.5% (p = 0.09) in men for hip fracture.

conclusionsThe Garvan Fracture Risk Calculator is valid and clinically useful in identifying individuals at high risk of fracture. The models with BMD performed better than those with body weight in fracture risk prediction.

Indexed as

NomogramsAdultAgedAged, 80 and overCohort StudiesFemaleFractures, BoneHip FracturesHumansMaleMiddle AgedNorwayOsteoporotic FracturesRisk AssessmentROC Curve

Identifiers

PMID25255221
PMCPMC4177811
OpenAlexW2160765668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.